M3 Biotechnology

Bothell, Wash.

M3 Biotechnology develops a therapy for Alzheimer’s disease designed to stop neuron deterioration.

Facts

HQ
Bothell, Wash.
Sectors
Biotechnology, Therapeutics, Neurodegenerative diseases

Is this your organization? Claim it

Recent coverage

Front-page news, podcasts and videos about M3 Biotechnology

See all 7

Athira Pharma prices IPO at $17, sells 12M shares to raise $204M; will trade as ATHA on Nasdaq

Seattle biotech Athira Pharma priced its IPO at $17 per share, selling 12 million shares to raise at least $204 million and will begin trading on Nasdaq under ticker ATHA; the company is developing NDX-1017 for neurodegenerative diseases and has no commercial products yet. Founded in 2011 and led by CEO Dr. Leen Kawas, Athira reported net losses in 2019 and H1 2020 and has raised over $100 million privately, including an $85 million Series B.

People

  • Leen Kawas Founder

Questions about M3 Biotechnology

What is M3 Biotechnology?

Bothell, Wash.

Who are the people behind M3 Biotechnology?

Seattle Flow lists Leen Kawas (Founder) at M3 Biotechnology.

Who invested in M3 Biotechnology, and how much has it raised?

Members of Seattle Flow see M3 Biotechnology's funding rounds, amounts and investors on its Funding tab. Joining is free.

Where is M3 Biotechnology based?

M3 Biotechnology is headquartered in Bothell, Wash..